1. A phase II trial of continuous ixazomib, thalidomide and dexamethasone for relapsed and/or refractory multiple myeloma: the Australasian Myeloma Research Consortium (AMaRC) 16‐02 trial. (15th May 2021) Authors: Bergin, Krystal; Yuen, Flora; Wallington‐Beddoe, Craig; Kalff, Anna; Sirdesai, Shreerang; Reynolds, John; Spencer, Andrew Journal: British journal of haematology Issue: Volume 194:Number 3(2021) Page Start: 580 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗